Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure

Sacubitril/valsartan is a novel medication that acts as a neprilysin and angiotensin receptor blocker.1 Its overwhelming benefit seen in its main clinical trial, PARADIGM-HF, led to its incorporation into the American College of Cardiology(ACC)/American Heart Association(AHA)/Heart Failure Society of America (HFSA) guidelines.2-4 In the PARADIGM-HF trial, sacubitril/valsartan demonstrated a reduction in the composite endpoint of cardiovascular death or hospitalization for worsening heart failure when compared to enalapril.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Research Letter Source Type: research